LLY news and market impact
Real-time Eli Lilly and Company news affecting stock and options prices
Latest LLY news
Novo Nordisk released clinical trial data showing its high-dose Wegovy (7.2mg) achieved 27.7% average weight loss in early responders at 72 weeks, compared to 21% overall and 17% for the previous 2.4mg dose.
Novo Nordisk released clinical trial data showing its high-dose Wegovy (7.2mg) achieved 27.7% average weight loss in early responders at 72 weeks, compared to 21% overall and 17% for the previous 2.4mg dose. The data was presented at the European Congress on Obesity one month after U.S. launch of the higher dose.
FDA Commissioner Marty Makary resigned following mounting backlash from pharmaceutical companies, physicians, and patient groups over regulatory decisions and faster vape approvals.
FDA Commissioner Marty Makary resigned following mounting backlash from pharmaceutical companies, physicians, and patient groups over regulatory decisions and faster vape approvals. Acting Commissioner Kyle Diamantas will temporarily take over the agency. The resignation ends a tenure marked by internal dysfunction and leadership turmoil.
Eli Lilly's oral GLP-1 drug has received FDA approval and is experiencing rapid market uptake.
Eli Lilly's oral GLP-1 drug has received FDA approval and is experiencing rapid market uptake. The oral formulation addresses a key barrier to GLP-1 adoption compared to injectable competitors, potentially expanding addressable market share in the diabetes and obesity treatment space.
Headline ingested without LLM analysis.
Headline ingested without LLM analysis
Headline ingested without LLM analysis.
Headline ingested without LLM analysis
Headline ingested without LLM analysis.
Headline ingested without LLM analysis
Headline ingested without LLM analysis.
Headline ingested without LLM analysis
Headline ingested without LLM analysis.
Headline ingested without LLM analysis
Headline ingested without LLM analysis.
Headline ingested without LLM analysis
Headline ingested without LLM analysis.
Headline ingested without LLM analysis
How news affects LLY
Eli Lilly and Company (LLY) is sensitive to: drug approvals, obesity drug demand, earnings, Medicare policy.Major pharma — GLP-1 weight loss drugs (Mounjaro/Zepbound), insulin.
Related tickers
Get LLY alerts before the market moves
AI-powered news filtering. Only what matters to your positions.
Start free trialFrequently asked questions
What is moving LLY today?
Novo Nordisk released clinical trial data showing its high-dose Wegovy (7.2mg) achieved 27.7% average weight loss in early responders at 72 weeks, compared to 21% overall and 17% for the previous 2.4mg dose.
How do I get LLY news alerts?
Sign up for Tradar and add LLY to your watchlist. You'll get push notifications for high-impact news within seconds.